Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 21;5:PO.21.00143. doi: 10.1200/PO.21.00143

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

FIG A1. — The response of patient-derived organoids to the anti-EGFR monoclonal antibody cetuximab. (A) Representative bright-field microscopy images of organoids treated with cetuximab for 7 days. MG-132 was used as a positive control for organoids' death (data not shown), whereas DMEM/F12 medium served as a negative control. Magnification: 10×. (B) At the end of the treatment, organoids' viability was measured by the CellTiter GLO assay and viability values were analyzed using GraphPad software. The results are the average of three independent experiments with technical quadruplicates, and error bars represent the standard deviation among biologic replicates. Z factor values varied between 0.75 and 0.82. Cmab, cetuximab; ctrl, control.